• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
3-Bromo-4-fluorobenzaldehyde
5-Methyl-1,3,4-oxadiazol2(3H)-one
4-Amino-6-methyl-3 oxo2,3, 4,5-tetrahydro 1.2.4-triazine hydrochloride
4-Acetylamino-6-methyl -3-oxo-2,3,4,5-tetrahydro-1,2,4-triazine
3-Pyridinecarboxaldehyde
Ethyl 3 Fluorobenzoate

Oncology biotech Tyra Biosciences files for a $100 million IPO

firstwordpharmaAugust 23, 2021

Tag: Tyra , FGFR , IPO

Tyra Biosciences, which is developing FGFR inhibitors for cancer, filed plans with the SEC to raise up to $100 million in an initial public offering, as reported in Renaissance Capital.

The company is using its proprietary SNÅP platform to generate next-generation candidates that are specifically designed to address acquired drug resistance and provide alternative treatment options.

Its lead candidate, TYRA-300, is designed to selectively inhibit FGFR3, with an initial focus on patients with bladder cancer.

Tyra anticipates filing an investigational new drug application for TYRA-300 in mid-2022.


Previous:South Korea to get more Moderna COVID shots in boost to vaccination effort

Next:UK scientists look at reducing boosters to save vaccine for rest of the world

Related News

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

BioPharmaSpec, the leading global Contract Research Organization (CRO) for Discovery and Preclinical Characterization of Biopharmaceuticals, has officially announced three new European facilities.

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Oncology biotech Tyra Biosciences files for a $100 million IPO | Pharmasources.com

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

PharmaSourcesNovember 15, 2024

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

You may like
More>>

Adipokinetic Hormone II from Schistocera gregaria

Adipokinetic Hormone II from Schistocera gregaria
Calciumbeta-hydroxy-beta-methylbutyrate

Calciumbeta-hydroxy-beta-methylbutyrate
Alpha lipoic acid

Alpha lipoic acid
Tripotassium glycyrrhizinate

Tripotassium glycyrrhizinate
Tripotassium Phosphate

Tripotassium Phosphate
ALPHA LIPOIC ACID（1077-28-7）

ALPHA LIPOIC ACID（1077-28-7）
Thioctic Acid(Alpha Lipoic Acid)

Thioctic Acid(Alpha Lipoic Acid)
Ethyl (S)-(-)-4-chloro-3-hydroxybutyrate

Ethyl (S)-(-)-4-chloro-3-hydroxybutyrate
Membrane extruder/Liposomes extruder/3

Membrane extruder/Liposomes extruder/3
Ethyl (R)-2-hydroxy-4-phenylbutyrate

Ethyl (R)-2-hydroxy-4-phenylbutyrate

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service